7月15日，科伦博泰生物盘中上涨10.8%，报552.0港元，成交额4.64亿港元。
消息面上，公司宣布核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌的三期临床研究已达到主要终点，安全性与既往研究一致，未观察到新的安全性信号。此前公司已在ASCO大会披露sac-TMT联合K药一线治疗PD-L1阳性NSCLC的三期阳性结果，本次PD-L1阴性适应症的突破进一步扩大其覆盖人群范围。国联民生证券此前研报指出，科伦博泰及合作方默沙东在PD-1单抗+ADC路线中兼具适应症覆盖范围与较高成功概率，有望在该路线中胜出。目前公司已在中国开展9项注册性临床研究。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.